{"url":"https://www.moneycontrol.com/news/business/granules-gets-usfda-nod-for-generic-gout-medication-12711335.html","title":"Granules gets USFDA nod for generic gout medication","description":"Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of the company, has received approval from the US Food \u0026 Drug Administration (USFDA) for Colchicine Capsules (0.6 mg), it said in a regulatory filing.Granules gets USFDA nod for generic gout medication","content":"Drug firm Granules India on Tuesday said it has received approval from the US health regulator to market a medication used to prevent or treat gout attacks. Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of the company, has received approval from the US Food \u0026 Drug Administration (USFDA) for Colchicine Capsules (0.6 mg), it said in a regulatory filing. The company's product is therapeutically equivalent to Hikma International Pharmaceuticals LLC's Mitigare Capsules (0.6 mg), it added. According to industry sources, the current annual market for Colchicine Capsules in the US is expected to be around USD 55 million. ","cleaned_content":"drug firm granules india on tuesday said it has received approval from the us health regulator to market a medication used to prevent or treat gout attacks granules pharmaceuticals inc a wholly owned foreign subsidiary of the company has received approval from the us food drug administration usfda for colchicine capsules \u003cZERO_\u003e mg it said in a regulatory filing the companys product is therapeutically equivalent to hikma international pharmaceuticals llcs mitigare capsules \u003cZERO_\u003e mg it added according to industry sources the current annual market for colchicine capsules in the us is expected to be around usd \u003cFIVE_TEN\u003e million","timestamp":"2024-04-30T11:39:00+05:30","market_timestamp":"2024-04-30T11:39:00+05:30","off_market_hours":false}